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ABC proteinThe cystic ﬁbrosis transmembrane conductance regulator (CFTR) plays a critical role in transcellular ion
transport and when defective, results in the genetic disease cystic ﬁbrosis. CFTR is novel in the ATP-binding
cassette superfamily as an ion channel that is enabled by a unique unstructured regulatory domain. This R
domain contains multiple protein kinase A sites, which when phosphorylated allow channel gating. Most of
the sites have been indicated to stimulate channel activity, while two of them have been suggested to be
inhibitory. It is unknown whether individual sites act coordinately or distinctly. To address this issue, we
raised monoclonal antibodies recognizing the unphosphorylated, but not the phosphorylated states of four
functionally relevant sites (700, 737, 768, and 813). This enabled simultaneous monitoring of their
phosphorylation and dephosphorylation and revealed that both processes occurred rapidly at the ﬁrst three
sites, but more slowly at the fourth. The parallel phosphorylation rates of the stimulatory 700 and the
putative inhibitory 737 and 768 sites prompted us to reexamine the role of the latter two. With serines 737
and 768 reintroduced individually into a PKA insensitive variant, in which serines at 15 sites had been
replaced by alanines, a level of channel activation by PKA was restored, showing that these sites can mediate
stimulation. Thus, we have provided new tools to study the CFTR regulation by phosphorylation and found
that sites proposed to inhibit channel activity can also participate in stimulation.© 2009 Published by Elsevier B.V.1. Introduction
A central region of the CFTR sequence, rich in consensus PKA
phosphorylation sites, was originally dubbed the R domain with the
implication that it might be involved in regulation of the cAMP
stimulated chloride conductance reported to be defective in CF
patients [1]. This has been conﬁrmed in general but the mechanism
by which it occurs is not fully understood. Many of the consensus PKA
sites can be phosphorylated both in vitro and in vivo and none of the
individual sites appears to be either necessary or sufﬁcient for
complete activation of the CFTR chloride channel by PKA [2–5]. Only
when approximately 15 sites are mutated, is there essentially no
residual response to PKA [6]. The idea that the unphosphorylated R
domain inhibits channel activity and phosphorylation releases theansmembrane Regulator; PKA,
ses; NBD, nucleotide binding
, Chapel Hill, NC, 27599, USA.
rdan).
lsevier B.V.inhibition is supported by the observation that deletion of a large
portion of the R sequence produces a constitutively active channel not
requiring PKA stimulation [7–9]. Additionally, it was reported that the
phosphorylated R domain was also inherently stimulatory in addition
to the inhibitory action of unphosphorylated R region [10]. However,
according to some evidence, most of the channel activation by PKA
appears to be due to relief of the inhibitory effect of the unpho-
sphorylated R domain [11].
Relative to the high degree of overall CFTR sequence conservation
phylogenetically, the R sequence is less conserved except for the
number and positions of the phosphorylation sites [12]. The negative
charges introduced by the addition of phosphoryl groups apparently
play an important role in the activation mechanism because
substitution of the phosphorylated hydroxyl amino acids by either
aspartate or glutamate results in partial constitutive channel activity
[13,14]. However, perturbations other than electrostatic changes such
as isomerization of proline residues in the R domain can also activate
the channel [15,16]. Changes in the secondary structure upon
activation by PKA also have been reported [17]. In spite of the low
content of formed secondary structural elements in the R domain [17–
19], these conformational alterations are apparently propagated to
1342 T. Hegedűs et al. / Biochimica et Biophysica Acta 1788 (2009) 1341–1349other regions of CFTR including the membrane-spanning domains as
revealed in hydrogen/deuterium exchange experiments [20].
Progressive removal of increasing numbers of the multiple PKA
sites by mutagenesis is generally consistent with an additive
mechanism, which could provide a graded or metered response to
channel activation [2,6,13,21–24]. This may be very relevant
physiologically where, in airway epithelial cells for example
under normal conditions, an intermediate level of CFTR mediated
chloride secretion occurs [25]. This intermediate level of chloride
current reﬂects the balance between the activity levels of PKA and
phosphatases that remove phosphoryl groups from these sites. An
aspect of this additive mechanism which has not been elucidated is
the relative contribution of each site. The conservation of their
distribution across the approximately 200 residues of the R domain
suggests that their location is important, but the relative propor-
tions of a maximal response contributed by each is unclear as is
whether they act independently or in a cooperative manner. There
are several suggestions that not all sites contribute equally. A large
reduction in channel activity is caused by mutagenesis of only four
sites (serines 660, 737, 795, and 813) [21]. When these sites as
well as all of the other dibasic consensus sites were substituted
(serines 686, 700, 712, 768, and threonine 788) activity was
further reduced [21], but additional monobasic sites were still able
to support a low level of activity [6,26]. Two of the dibasic sites at
serines 737 and 768 have been described as distinctly different
from the others, playing inhibitory rather than stimulatory roles
when phosphorylated [21–24].
Here we introduce monoclonal, anti-R domain antibodies to
investigate the phosphorylation state of individual phosphorylation
sites in the CFTR R domain. It is demonstrated that these antibodies
enable the facile detection of phosphorylation and dephosphorylation
of multiple individual sites simultaneously and reveal differences
among them. Experiments employing constructs with a mutation of a
single serine to alanine to abolish the phosphorylation at a speciﬁc
site, suggest a possible inﬂuence of the phosphorylation of one site on
that of others. Since we observed that the phosphorylation state of the
proposed inhibitory sites changed in parallel with that of the
stimulatory sites, we also investigated the inﬂuence of the phosphor-
ylation of the inhibitory sites on the single channel activity of the
protein from which all of the stimulatory sites had been removed by
mutagenesis [6]. In this background, reintroduction of serines at
positions 737 and 768, or both, restored a signiﬁcant level of response
to channel activation by PKA, indicating that while normally there are
probably speciﬁc effects of each site, the impact of an individual site is
context-dependent.
2. Materials and methods
2.1. Materials
The PKA catalytic subunit was from Promega (Madison, WI, USA).
All other chemicals were from Sigma (St Louis, MO, USA). The four
phosphorylation-sensitive R domain and the phosphorylation insen-
sitive anti-NBD2 (Ab 596) antibodies were generated as has been
described in detail [27]. Brieﬂy, puriﬁed CFTR used as immunogenwas
emulsiﬁed inmouse RIBI™ adjuvant (RIBI ImmunoChemResearch, MT,
USA) and injected intraperitoneally into Balb/c mice at ∼40 μg per
animal followed by twomore injections after 3 and 6 weeks. Antibody
titers in sera were determined by (ELISA) in 96 well Imobilon plates
with 1–2 μg immobilized protein per well. Two mice with the highest
titers received a ﬁnal booster injection four days before their spleens
were removed. The cells in the spleens were dissociated and fused
with the myeloma cell line P3X63-Ag8.653. Hybridoma supernatants
were screened by ELISA and Western blots. Epitopes were mapped
using different segments of the CFTR sequence (expressed either in
bacteria or BHK cells) and ﬁnally overlapping 8-mer peptides.Phosphorylated and unphosphorylated peptides corresponding to
the epitopes of four of the antibodies (700: KRKNSILNPIN; 737:
DEPLERRLSLVPDS; 768: PRISVISTGPTLQARRRQSVLN; 813: DIYSRRLS-
QETGLE) were synthesized by Abgent (San Diego, CA). Underlined
residues were phosphorylated in the phosphorylated forms of the
peptides.
2.2. Cell lines and constructs
BHK-21 cells stably expressing WT CFTR were used as a model
system [2], while Calu-3 cell lines were utilized as a model for
epithelial cells expressing endogenous CFTR. Mutant constructs were
generated by polymerase chain reaction (PCR) using pcDNA3, which
contained full length CFTR, as a template. PCR was done by Quick
Exchange (Stratagene) according to the manufacturer's protocol, and
the products were sequenced. Mutant proteins were stably expressed
in BHK-21 cells by cotransfection with the pNUT plasmid to provide a
selectable marker [28]. The media of transfected cells was supple-
mented with 500 μMmethotrexate. All cell lines were grown at 37 °C.
2.3. Membrane vesicle isolation from BHK-21 cell
Membranes from CFTR expressing BHK cells were isolated as
described earlier [29]. After the ﬁnal centrifugation step they were
resuspended in phosphorylation buffer (10 mM HEPES, pH 7.2
containing 0.5 mM EGTA, 2 mM MgCl2, and 250 mM sucrose). Brief
bath sonication (three 20 s periods) was used to generate vesicles of
uniform size for single channel measurements. The membranes were
aliquoted and stored at −80 °C until used.
2.4. Western blotting and peptide competition
Samples were subjected to SDS-PAGE and transferred to nitrocel-
lulose membrane. Membranes were incubated with a mixture of one
of the phosphorylation-sensitive, R domain speciﬁc antibody (IgG1
subtype) and the phosphorylation insensitive 596 antibody (IgG2b
subtype). In the peptide competition experiments, the antibodies
were preincubated with the corresponding peptides for 1 h at room
temperature. Peptide concentrations applied were 0.7 μM, 5.8 μM,
0.4 μM, and 5.7 μM for peptides covering epitopes 700, 737, 768, and
813, respectively. Isotype speciﬁc secondary antibodies were used
with different dyes coupled: Alexa Fluor 680 goat anti-mouse IgG2b
(Molecular Probes) and IRDye 800CW rabbit anti-mouse IgG1 (Rock-
land). Signals were detected using an Odyssey laser scanner (LiCor
Biosciences, NE, USA). Data from at least three independent experi-
ments were quantiﬁed using the Odyssey software (LiCor Biosciences,
NE, USA).
2.5. Phosphorylation of isolated membrane
Membranes were aliquoted into Eppendorf tubes to a ﬁnal
concentration of 1 μg/μl in 50 μl of phosphorylation buffer containing
protease inhibitors (10 μg/ml leupeptin, 20 μg/ml aprotinin, 35 μg/ml
E64, and 1.2 mg/ml benzamidine), phosphatase inhibitor calyculin A
(2 μM), and NP40 (0.2%). The phosphorylation reaction was initiated
by adding 50 μl of phosphorylation buffer supplemented with PKA
catalytic subunit (200 U/ml) and ATP (2 mM). For the unpho-
sphorylated (0 min) control phosphorylation buffer was added. The
reactionwas stoppedwith 100 μl Laemmli sample buffer and the tubes
placed in ice. Samples (2.5 μg) were loaded into each lane for SDS-
PAGE. The labeling by phosphorylation-sensitive antibodies (% Initial
signal) was calculated in two steps. First, the integrated intensity
values in the 800 nm channel (phosphorylation-sensitive signal) were
normalized to the values in the 700 nm channel (signal of
phosphorylation insensitive 596 Ab) to correct for the protein
amount: F800 nm, ti, corrected=F700 nm, t0/F700 nm, ti×F800 nm, ti, where
Fig.1. Phosphorylation at four R domain sites is detectable by phosphorylation-sensitive
antibodies. Membranes isolated from BHK cells expressingWT CFTR were incubated for
32 min in the presence or absence of puriﬁed PKA catalytic subunit (70 U/ml) and ATP
(2 mM). The phosphorylation reaction was stopped with Laemmli sample buffer and
samples were placed on ice. After electrophoresis and Western blotting, samples were
probed with monoclonal, phosphorylation-sensitive, anti-R domain antibodies (α700,
α737, α768, α813; IgG1 subtype; top row) and the phosphorylation insensitive, anti-
NBD2 596 antibody (IgG2b subtype; bottom row) as an internal control of protein
amount. Secondary antibodies of different subtypes and with different ﬂuorescent dyes
(λEM 700 and λEM 800) were used for scanning with Odyssey infra red imager (LiCor
Biosciences, NE, USA).
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area of the CFTR band; t0 and ti indicate the bands representing the
unphosphorylated sample at the zero time point and the sample
subjected to phosphorylation for ti minutes, respectively. Second, the
maximal labeling of the unphosphorylated sample was considered as
100% of labeling: % Initial signal=F800 nm, ti, corrected/F800 nm, t0×100.
2.6. Phosphorylation and dephosphorylation of CFTR in cells
Cells were grown to approximately 90% conﬂuency in 60 mm Petri
dishes. After PBS washing, regular media was replaced with media
without serum containing 0 or 10 μM forskolin. Cells were incubated
at 37 °C for different lengths of time. Phosphorylation was stopped by
lysis of the cells with sample buffer and placing them on ice. 10 μg of
total protein was loaded for SDS-PAGE.
To follow dephosphorylation in cells, phosphorylation was
stimulated with 10 μM forskolin for 15 min. Then cells were washed
quickly and incubated in regular media for various periods of time,
then prepared for Western blotting. The labeling was quantiﬁed in the
same way as in the experiments with isolated membranes.
2.7. Single channel measurements
Planar lipid bilayers were created as described earlier in detail [30].
Membrane vesicles prepared from BHK cells expressing CFTR
constructs were treated with 100 U/ml PKA and 2 mM Na2ATP in
phosphorylation buffer for 15 min at room temperature, and then
fused to the preformed lipid bilayer spontaneously. Chambers
containing symmetrical solutions (300 mM Tris–HCl, 3 mM MgCl2,
1 mM EGTA, pH 7.2 on either side of the bilayer), were thermostated
and stirred. Voltage clamp conditions at Vm=−75 mV were used to
record CFTR single channel currents. At least three independent
experiments were used for each constructs to calculate average Po
values and standard errors. Representative traces are shown in the
ﬁgures.
3. Results
3.1. Monoclonal antibodies detect the phosphorylation state of four R
domain sites
Phosphorylation of multiple sites within the R domain has been
measured by phospho-peptide mapping using the 32P radioisotope
and by mass spectrometry [4,13,31–33]. To enable more facile
monitoring of several sites simultaneously, we utilized phosphoryla-
tion-sensitive monoclonal antibodies. Detection of CFTR pretreated
with PKAwas strongly diminished in Western blots probed with a set
of these antibodies, while the signal detected by the 596 antibody
recognizing an epitope in NBD2 [27] was unaltered (Fig. 1). Epitope
mapping of four, phosphorylation-sensitive mouse monoclonal anti-
bodies raised against the puriﬁed human protein [27] revealed that
they recognized short linear sequences containing PKA phosphoryla-
tion sites in the R domain including those at serines 700, 737, 768, and
813. As shown in Fig. 2A, synthetic peptides corresponding to each of
these sites effectively competed for the detection of CFTR by the
relevant antibody inWestern blots. However, when the serines, which
are phosphorylated in the full length protein, were replaced by
phosphoserines in these peptides, the competing ability was lost. This
conﬁrms the speciﬁcity of these antibodies for four different sites
known to be involved in CFTR channel regulation and indicates that
the replacement of the serine hydroxyl group in each with a
phosphoryl group strongly diminishes recognition. Thus on the basis
of these synthetic peptide competition experiments, the four
antibodies had the capability of detecting the phosphorylation state
of CFTR. Since the phosphorylation level of the channel has been
shown to correlate with its activation-state [2,21], the labeling bythese phosphorylation-sensitive antibodies, to some extent, indirectly
characterize the activation level of CFTR. As reagents that detect
unphosphorylated but not phosphorylated sites, these antibodies are
the inverse of those commonly developed tomonitor phosphorylation
of many signaling proteins, where antibodies recognize an epitope
containing a phosphorylated but not an unphosphorylated amino
acid. Our reagents serve the same purpose, however, just utilized in a
reciprocal mode.
Additional evidence that the loss of delectability by each of these
epitopes was due to serine phosphorylation came from experiments,
in which each serine was substituted with an alanine. First, when this
was done at each site separately, it was found that Western blot
signals were no longer sensitive to phosphorylation by PKA (Fig. 2B).
In all four cases, signals were weaker than when the native serines
were present. In the case of the S700 site the alanine substitution
almost completely destroyed the epitope indicating that this serine is
an essential part of that epitope. Most importantly, however, in all four
cases when serines are no longer present, detection by these
antibodies is no longer inﬂuenced by PKA phosphorylation of the
protein. Similar results were obtained when the serines at all PKA
phosphorylation sites were replaced simultaneously with alanines
(Fig. 2C).
3.2. Relative rates of phosphorylation of 700, 737, 768, and 813 sites
The utilization of our antibodies to study the kinetics of
phosphorylation is illustrated in Fig. 3, where the time course of
phosphorylation of each of the sites is followed at the same time. The
ﬁrst three sites (700, 737, and 768) all respond rapidly to phosphor-
ylation by PKA added to CFTR containing membranes with near
maximal extinction of their detection by the corresponding antibodies
within 2min, the shortest time at whichmeasurements weremade. In
fact, the Ser 700 site appeared to be more completely phosphorylated
during this initial interval, followed by the 737 and 768 sites whose
signals continued to diminish slightly till 8 min. Thus, within the range
of this assay, these sites appeared to be phosphorylated more or less
simultaneously with perhaps a slight indication of order in the N- to C-
terminal direction.
The most C-terminal 813 site exhibited a very different time
course, indicating that this site, which is known to play a role in
channel activation by PKA [21], is phosphorylated much more slowly
than the other three. The rate constant for the pseudo-ﬁrst order
phosphorylation reaction of site 813 (0.1 min−1) was determined
from the log plot of the labeling, while the rates of the other sites can
Fig. 2. Conﬁrmation of the role of phosphorylation in the decreased recognition by the four antibodies. (A) Peptide competition. Phosphorylation speciﬁc R domain antibodies were
preincubated with non-phosphorylated or phosphorylated peptides covering their epitopes for 1 h. Western blots of WT CFTR were probed with the preincubated antibodies as
described in Materials and methods. (B, C) Effect of serine to alanine substitutions on epitopes. The serines subject to phosphorylationweremutated to alanine individually (B) or all
together (C) preventing the possibility of phosphorylation. Membranes isolated from BHK cells expressing the mutants were treated with puriﬁed PKA catalytic subunit (70 U/ml)
and ATP (2 mM) for 0, 2, 4, 8, 16, 32, and 64 min (lines 1–7, respectively). The phosphorylation independent labeling of the SA mutants is shown by Western blots probed with the
phosphorylation-sensitive antibodies. The phosphorylation insensitive Ab 596 was used as a control for protein amount.
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greatly reduced rate of Ser 813 phosphorylation compared to the three
other, more N-terminal sites in intact CFTR, is in agreement with the
observations of Csanady et al. [24], who employed radio labeling and
mass spectrometry to follow the kinetics of phosphorylation of an
isolated recombinant R domain.
Because these time courses indicated that apparently there is at
least some temporal order in the phosphorylation of these four sites
we tested whether they inﬂuenced each other by determining how
removal of each by mutagenesis inﬂuenced the others (Fig. 4). In
general the rapid rate of phosphorylation of each of the more N-
terminal sites (700, 737, and 768) was not changed by alaninesubstitution at any of the three other sites, suggesting that any order in
their phosphorylation does not reﬂect interdependence among them.
On the other hand, the much lower rate of S813 phosphorylation
appeared to be reduced somewhat further by either the S700A or
S737A substitutions, but not by the S768A substitution. Thus, in
unmodiﬁed CFTR the early phosphorylation of the 700 and 737 sites
may promote the phosphorylation of the 813 site.
3.3. Phosphorylation states of individual sites in cells
The level of CFTR channel activity in cells is believed to reﬂect the
phosphorylation state of the multiple R domain PKA sites determined
Fig. 3. Phosphorylation rates at different sites. Membranes were prepared from CFTR expressing BHK cells and treated with PKA for 0, 2, 4, 8, 16, 32, and 64 min at room temperature.
(A) The phosphorylation rate of sites 700, 737, 768, and 813was followed byWestern blotting. (B) The bands were quantiﬁed using the Odyssey (LiCor Biosciences, NE, USA) software
and normalized to the signal with the phosphorylation insensitive Ab 596, and related to the unphosphorylated sample (0min) as detailed in theMaterials andmethods section. Data
are derived from at least three independent experiments and plotted against time.
Fig. 4. Inﬂuence of individual site substitutions on the phosphorylation of the others. Membranes isolated from BHK cells expressing S700A (A), S737A (B), S768A (C), or S813A (D)
were subjected to phosphorylation for 0, 2, 4, 8, 16, 32, and 64 min. Western blots were probed with each of the phosphorylation-sensitive anti-R domain antibodies and the
phosphorylation independent Ab 596 as an internal control for quantiﬁcation. Signals were detected and quantiﬁed using an Odyssey infra red scanner and software. Signals at the
mutated site are not plotted as they did not change (see Fig. 2B).
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sites. We employed the antibodies to detect the impact of exposure of
cells to 10 μM forskolin, a treatment identical to that which causes full
activation of the channel. A striking overall difference in the change in
phosphorylation of the individual sites over time compared with thatFig. 5. Kinetics of phosphorylation of CFTR in cells. Phosphorylation kinetics of sites 700,
737, 768, and 813 was followed in Calu-3 cells expressing CFTR endogenously (A), BHK
cells heterologously expressing the wild type (B), and the 1440X mutant with a C-
terminal deletion lacking the PP2A binding site (C). Cells were incubated in the absence
or presence of 10 μM forskolin. After the indicated times cells were lysed in Laemmli
sample buffer and subjected to Western blotting. Signals were detected and quantiﬁed
as described in Materials and methods (n=3).
Fig. 6. Rate of dephosphorylation of individual sites in cells. Calu-3 (A), BHK WT CFTR
(B), and BHK 1440X CFTR (C) cell lines were treated with 10 μM forskolin. After 15 min
of stimulation the incubation buffer was replaced with regular media to allow
phosphatases to act before harvesting the cells at the indicated times. Cell lysates were
subjected to Western blotting, and the quantiﬁed data are plotted after normalization
(n=3).in PKA treatedmembranes was the occurrence of the response in cells
with two modes, reﬂecting the initial adenylate cyclase and PKA
activation followed by the counter effects of cellular phosphatases
(Fig. 5). Thus, in cells treated only with forskolin, there is rapid
phosphorylation but to a lesser extent than in PKA treatedmembranes
because dephosphorylation begins before the phosphorylation by
Fig. 7. Alanine substitutions at S737 and S768 decrease the activity of the stimulated channel. Single channel currents from membranes expressing WT and the SA mutants were
recorded at 30 °C in unphosphorylated (A) and phosphorylated (B) states. Po values were calculated from currents recorded for at least 20 min and ∼100 second long representative
traces are shown. Numbers of independent experiments are denoted (n). Currents for open and closed states are marked with O and C, respectively.
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and 768 sites of the endogenously expressed CFTR in Calu-3 cells
where a transient level of maximum phosphorylation is reached
immediately followed by signiﬁcant dephosphorylation (Fig. 5A). In
BHK cells heterologously expressing CFTR, the phosphorylation level
is generally higher indicating a lower level of dephosphorylation. In
both cell types, S813 is phosphorylated at a rate only slightly less than
that of the other sites, whereas this rate was very much less in PKA
treated membranes.
Since both phosphorylation and dephosphorylation took place in
the above experiments, we employed an alternative protocol to
investigate dephosphorylation. In these experiments, cells were ﬁrst
exposed to forskolin to achieve a highly phosphorylated state and
then transferred to forskolin-free medium. The time course of
dephosphorylation by endogenous cellular phosphatases was then
followed (Fig. 6). As with phosphorylation, both in isolated PKA
treated membranes and forskolin-treated cells, dephosphorylation of
sites 700, 737, and 768 occurred quite rapidly in both Calu-3 (Fig. 6A)
and BHK (Fig. 6B) cells, although at a higher rate in the latter. The S813
site was dephosphorylated considerably more slowly than the other
sites in BHK cells (Fig. 6B), very similarly to the relative rates of
phosphorylation of S813 versus the other 3 sites in isolated
membranes (Fig. 3). In Calu-3 cells, where the rates of depho-
sphorylation of all sites were less than the BHK, the 813 site was
dephosphorylated very much more slowly. Interestingly, a similar
slow rate of dephosphorylation was observed with a C-terminally
truncated CFTR (1440X) missing a sequence to which one isoform ofFig. 8. Reintroduction of S737 or S768 back into the 15SA construct increases channel activit
and currents were recorded at 30 °C at least for 20 min. Po values were calculated for th
independent experiments are indicated (n). Currents for open and closed states are markedPP2A binds [34]. This phosphatase may act on the 813 site in full
length CFTR in BHK cells but perhaps not in Calu-3 cells. There have
been suggestions, from their effects on CFTR channel activity, that
different phosphatases (e.g. PP2A and PP2C) may act on different sites
[35].
3.4. The functional role of the sites at serines 737 and 768
Our data indicate that the ﬁrst three sites undergo dephosphor-
ylation with parallel kinetics just as with their phosphorylation.
Simultaneous changes in the phosphorylation state of stimulatory
(700) and inhibitory (737 and 768) sites was unexpected and led us to
reexamine the role of the latter two sites. Substitution of each serine
with alanine indeed caused a small increase in the basal open
probability (Po) of the channel (Fig. 7). However, when fully activated
by PKA each of the individual mutants exhibited reduced rather than
increased Po (Fig. 7 and Fig. S2A). To more directly test this impact of
phosphorylation of these two serines, a variant in which response to
PKAwas completely ablated by substitution of serines and threonines
with alanines at 15 PKA sites was employed [6]. Serines were
reintroduced at the 737 and 768 positions in this background and
basal and PKA stimulated single channel activitymonitored (Fig. 8 and
Fig. S2B). The presence of either of these two serines had no effect on
basal activity, but restored a signiﬁcant response to PKA. Thus
phosphorylation of each site is capable of stimulating substantial
gating activity. Hence, in this context we ﬁnd no evidence for an
inhibitory role of these two sites.y. Membranes without (A) or with (B) PKA treatment were fused to planar lipid bilayer
e full period, while ∼100 second long representative traces are shown. Numbers of
with O and C, respectively.
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Phosphorylation-sensitive, monoclonal antibodies have been used
to study the phosphorylation of individual sites in the CFTR R domain.
These new tools enable monitoring of phosphorylation events at
speciﬁc sites in the full length CFTR expressed in cells. The rate of the
phosphorylation at individual sites was measured and revealed a
differential action of PKA on the four sites. Our observations that the
phosphorylation rate at S737 and S768 is similar to that of the
stimulatory sites and the phosphorylation of these sites in the 15SA
background increases channel activity indicate that the stimulatory or
inhibitory roles of these locations may be dependent on cell type,
temperature, and other unknown factors. Here, we also show that
phosphatases also act differentially on those sites.
Although phosphorylation site speciﬁc antibodies have been
developed and widely used in other research areas (such as signal
transduction and transcriptional regulation) for monitoring of protein
phosphorylation and its role in the control of the associated biological
function (http://www.exactantigen.com/review/phospho-antibody.
html), till now there was no easy way to follow phosphorylation of
individual serines or threonines in the CFTR R domain. We have
developed antibodies with the ability to detect phosphorylation of
individual sites in the R domain. Upon phosphorylation of the channel,
the recognition of epitopes containing serines 700, 737, 768, 813 is
greatly decreased (Fig. 1). Speciﬁcity of the change in recognition
upon phosphorylation is shown by peptide competition experiments
(Fig. 2A) and mutants with serines at phosphorylation sites mutated
to alanine (Fig. 2B and C). All four locations recognized by our
antibodies are known to be important sites for channel function
[6,23,24,36].
A primary question regarding CFTR regulation by phosphorylation
is whether or not there is a speciﬁc set of phosphorylation sites
responsible for the channel activation. It has been shown that
combined mutation of several serines (e.g. 4SA, 8SA, and 10SA) did
not completely abolish PKA dependent activation [2,13] indicating the
redundancy of phosphorylation sites for activation. It has been also
observed by others that there is some order in the phosphorylation of
different PKA sites in stimulated Xenopus oocytes [24]. Our observa-
tion, that phosphorylation of sites 700, 737, and 768 is an early event,
while serine 813 is phosphorylated more slowly (Fig. 3), is in general
agreement with data obtained in the non-mammalian system [24].
There may be greater order among other sites on a ﬁner time scale.
The diverse phosphorylation rates could reﬂect the inﬂuence of the
phosphorylation state of one site on the others. The phosphorylation
of the rapidly phosphorylated sites may increase the accessibility of
later sites. To test this hypothesis, serines at each of the four sites were
individually mutated to alanine and the phosphorylationwas followed
at the other three sites. In contrast to the study of Csanady et al. [24]
we could demonstrate a slightly reduced phosphorylation rate of S813
by removal of either S700 or S737 (Fig. 4). The source of the difference
may be the sensitivities of different assays used or the different
expression systems. In both their studies and ours, alanine mutants
were used to prevent phosphorylation at a given site. However,
alanine substitutions of some of these sites is known to inﬂuence the
conformation and the dynamics of the R domain [37] perhaps making
it somewhat similar to the activated conformation as we proposed in a
recent computational study [19]. Therefore it is possible that employ-
ing alanine mutants is not an adequate means to study the effect of
one site on the others, as the functional interaction between the sites
may be perturbed or masked.
The phosphorylation-sensitive antibodies provide facile detection
of CFTR phosphorylation in cells. The ﬁrst interesting observation was
the higher phosphorylation rate of site 813 in cells (Fig. 5) than in
isolated membrane vesicles (Fig. 3) which was unanticipated. Since
the experiments with membranes were performed at room tempera-
ture, while the studies on cells were performed at 37 °C, we repeatedthe experiments with isolated membranes at physiological tempera-
ture and ruled out temperature as being responsible for the difference
(Fig. S1). The retarded kinetics of phosphorylation of that most C-
terminal R domain site in isolated membranes may be caused by
differences in accessibility of this site or in the set of kinases acting on
the site 813 in a cellular environment compared to the isolated
membranes treatedwith PKA. Thereforewe hypothesize that different
stimulatory mechanisms present in cells, involving for example other
kinases [38], lipids [39], intracellular or extracellular factors [40,41]
account for this difference. The extent of phosphorylation of all sites
was signiﬁcantly lower in cells than in membranes (Figs. 3 and 5),
which is not unexpected, as there are fewer phosphatases present,
some of which are inhibited by calyculin A present in the incubation
buffer.
Even though the action of phosphatases on CFTR has been studied
in less detail than the stimulatory kinase effect, dephosphorylation
plays as a crucial role in the channel regulation as phosphorylation. It
has been shown that PP1 does not act on CFTR [42,43], while CFTR is a
substrate for PP2A [42,44,45], PP2B [46], and PP2C [43,47,48]. Here we
present for the ﬁrst time experimentally in our dephosphorylation
studies in cells (Fig. 6) a differential inﬂuence of phosphatases, similar
to that of kinases. The dissimilar rates of dephosphorylation at
different sites might be caused by either the different rate of
dephosphorylation by one phosphatase or the action of different
phosphatases with different afﬁnities for the phosphorylation sites.
The interaction between CFTR and PP2A was shown to be localized to
the extreme C-terminus of CFTR [34]. To investigate the speciﬁc role of
PP2A on R domain dephosphorylation we utilized a 1440X construct
lacking the last forty amino acids. The dephosphorylation rate in this
construct was decreased at all sites indicating the importance of
dephosphorylation of CFTR by PP2A. It is not possible to distinguish,
whether the remaining dephosphorylation is caused by other
phosphatases or some PP2A isozymes that do not require this speciﬁc
interaction with CFTR for their action on this chloride channel. In
summary, our experiments with these four antibodies demonstrate
the presence of the delicate balance of kinases and phosphatases in
CFTR phosphorylation reﬂected in the biphasic time courses of
changes in phosphorylation state in Fig. 5 and the distinct phospha-
tase sensitivity of different sites in Fig. 6. This balance of kinase and
phosphatase action on the R domain also has not been directly
demonstrated previously.
Interestingly, sites 737 and 768, which were reported to be
inhibitory [2,6,13,21–24], are phosphorylated and dephosphorylated
in parallel with the stimulatory sites 700 and 813 in the cell lines we
used. Therefore we performed detailed single channel measurements
to study the role of these sites in CFTR regulation (Figs. 7 and 8). The
S737A and S768A constructs exhibit slightly higher basal open
probability (Po=0.06) compared to wild type (Po≪0.01) in good
agreement with data of Csanady et al. [24]. However, after PKA
phosphorylation both mutants show signiﬁcantly lower activity
(Pob0.4) than the wild type (Po∼0.5) (Fig. 7). Moreover, their
stimulatory role is clearly displayed after reintroduction of serines at
position 737 or 768 in the PKA insensitive 15SA CFTR (Fig. 8). The
channel properties of the S737A mutant were previously reported to
be very similar to those of the wild type by Wilkinson et al. [10]. It is
also important to note that the inhibitory role of site 737 in the studies
of Baldursson et al. was exhibited only when serines 660, 795, and 813
were intact [22]. This may also indicate possible interactions between
various phosphorylation sites, however, this type of interplay was not
detected at all by Csanady et al. [24] or only minimally in our
experiments (Fig. 4). In order to interpret the data obtained from
experiments with the serine to alanine mutants, it is important to
realize that the alanine mutation does not completely recapitulate the
non-phosphorylated state of serine or threonine. Intramolecular,
inhibitory interactions of regions containing S737 and S768 may be
seriously destabilized in the alanine mutants (19), which may explain
1349T. Hegedűs et al. / Biochimica et Biophysica Acta 1788 (2009) 1341–1349the higher basal activity of the serine to alaninemutants. However, the
explanation of increased activity of the activated channel is not
immediately obvious. It has been shown that CFTR with the R domain
deleted also exhibits a slow-gating mode and a high Po mode, in
addition to the normal mode [49]. We have also detected these
different gating modes in WT CFTR (unpublished), and other authors
have reported the high Po mode for WT CFTR [50,51]. Besides the
context-dependent function of S737 and S768, one may speculate that
under certain experimental conditions, perhaps in Xenopus oocytes
[24], mutation of these serines to alanine may promote the high
Po mode.
In summary, the phosphorylation-sensitive antibodies provide an
efﬁcient tool to follow the phosphorylation of individual sites in the
CFTR R domain in vitro and in vivo. Analysis of the phosphorylation
kinetics indicates that the ordered action of kinases and phosphatases
may play a role in the additive mechanism of CFTR regulation by the R
domain. The results indicate that this complex regulatory mechanism
may be complicated further by the context-dependent inhibitory or
stimulatory roles of individual sites.
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